

Piśmiennictwo

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*. 2014; 129(8): 837–847, doi: [10.1161/CIRCULATIONAHA.113.005119](#), indexed in Pubmed: 24345399.
2. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. *Am J Cardiol*. 2009; 104(11): 1534–1539, doi: [10.1016/j.amjcard.2009.07.022](#), indexed in Pubmed: 19932788.
3. Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. *Europace*. 2011; 13(8): 1110–1117, doi: [10.1093/europace/eur132](#), indexed in Pubmed: 21551478.
4. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke*. 1996; 27(10): 1760–1764, doi: [10.1161/01.str.27.10.1760](#), indexed in Pubmed: 8841325.
5. Tu HTH, Campbell BCV, Christensen S, et al. Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. *Cerebrovasc Dis*. 2010; 30(4): 389–395, doi: [10.1159/000316886](#), indexed in Pubmed: 20693794.
6. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994; 154(13): 1449–1457, doi: [10.1001/archinte.1994.00420130036007](#), indexed in Pubmed: 8018000.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007; 146(12): 857–867, doi: [10.7326/0003-4819-146-12-200706190-00007](#), indexed in Pubmed: 17577005.
8. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014; 383(9921): 955–962, doi: [10.1016/S0140-6736\(13\)62343-0](#), indexed in Pubmed: 24315724.
9. Steinberg BA, Greiner MA, Hammill BG, et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. *Cardiovasc Ther*. 2015; 33(4): 177–183, doi: [10.1111/1755-5922.12129](#), indexed in Pubmed: 25930214.
10. O'Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. *Am Heart J*. 2014; 167(4): 601–609.e1, doi: [10.1016/j.ahj.2013.12.014](#), indexed in Pubmed: 24655711.
11. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? *Arch Intern Med*. 2000; 160(1): 41–46, doi: [10.1001/archinte.160.1.41](#), indexed in Pubmed: 10632303.
12. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events–European Registry in Atrial Fibrillation (PREFER in AF). *Europace*. 2014; 16(1): 6–14, doi: [10.1093/europace/eut263](#), indexed in Pubmed: 24084680.
13. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. *Europace*. 2014; 16(3): 308–319, doi: [10.1093/europace/eut373](#), indexed in Pubmed: 24351881.
14. Beyer-Westendorf J, Ehlik B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. *Europace*. 2016; 18(8): 1150–1157, doi: [10.1093/europace/euv421](#), indexed in Pubmed: 26830891.
15. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. *Stroke*. 2007; 38(2 Suppl): 624–630, doi: [10.1161/01.STR.0000250166.06949.95](#), indexed in Pubmed: 17261703.
16. Handke M, Harloff A, Hetzel A, et al. Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation—a transesophageal echocardiographic study in 500 patients with cerebral ischemia. *J Am Soc Echocardiogr*. 2005; 18(12): 1366–1372, doi: [10.1016/j.echo.2005.05.006](#), indexed in Pubmed: 16376768.
17. Mügge A, Kühn H, Nikutta P, et al. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. *J Am Coll Cardiol*. 1994; 23(3): 599–607, doi: [10.1016/0735-1097\(94\)90743-9](#), indexed in Pubmed: 8113541.
18. Sahin T, Ural D, Kilic T, et al. Evaluation of left atrial appendage functions according to different etiologies of atrial fibrillation with a tissue Doppler imaging technique by using transesophageal echocardiography. *Echocardiography*. 2009; 26(2): 171–181, doi: [10.1111/j.1540-8175.2008.00794.x](#), indexed in Pubmed: 19207995.
19. Takada T, Yasaka M, Nagatsuka K, et al. Blood flow in the left atrial appendage and embolic stroke in nonvalvular atrial fibrillation. *Eur Neurol*. 2001; 46(3): 148–152, doi: [10.1159/000050788](#), indexed in Pubmed: 11598333.
20. Tamura H, Watanabe T, Nishiyama S, et al. Prognostic value of low left atrial appendage wall velocity in patients with ischemic stroke and atrial fibrillation. *J Am Soc Echocardiogr*. 2012; 25(5): 576–583, doi: [10.1016/j.echo.2012.01.012](#), indexed in Pubmed: 22326133.
21. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. *J Am Coll Cardiol*. 2012; 60(6): 531–538, doi: [10.1016/j.jacc.2012.04.032](#), indexed in Pubmed: 22858289.
22. Masoudi FA, Calkins H, Kavinsky CJ, et al. American College of Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions. 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. *J Am Coll Cardiol*. 2015; 66(13): 1497–1513, doi: [10.1016/j.jacc.2015.06.028](#), indexed in Pubmed: 26133570.
23. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol*. 2013; 61(25): 2551–2556, doi: [10.1016/j.jacc.2013.03.035](#), indexed in Pubmed: 23583249.
24. Santoro G, Meucci F, Stolicova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. *EuroIntervention*. 2016; 11(10): 1188–1194, doi: [10.4244/EIJY14M10_13](#), indexed in Pubmed: 25354761.
25. Boersma LVA, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *Eur Heart J*. 2016; 37(31): 2465–2474, doi: [10.1093/eurheartj/ehv730](#), indexed in Pubmed: 26822918.
26. Reddy VY, Akehurst RL, Armstrong SO, et al. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. *J Am Coll Cardiol*. 2015; 66(24): 2728–2739, doi: [10.1016/j.jacc.2015.09.084](#), indexed in Pubmed: 26616031.

27. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Kardiol Pol.* 2016; 74(12): 1359–1469, doi: [10.5603/KP.2016.0172](#), indexed in Pubmed: [28009037](#).
28. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016; 37(38): 2893–2962, doi: [10.1093/eurheartj/ehw210](#), indexed in Pubmed: [27567408](#).
29. Piccini JP, Sievert H, Patel MR. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. *Eur Heart J.* 2017; 38(12): 869–876, doi: [10.1093/eurheartj/ehw330](#), indexed in Pubmed: [27628431](#).
30. Kamel H, Okin PM, Elkind MSV, et al. Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. *Stroke.* 2016; 47(3): 895–900, doi: [10.1161/STROKEAHA.115.012004](#), indexed in Pubmed: [26786114](#).
31. Piccini JP, Stevens SR, Chang Y, et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation.* 2013; 127(2): 224–232, doi: [10.1161/CIRCULATIONAHA.112.107128](#), indexed in Pubmed: [23212720](#).
32. Cox JL. Mechanical closure of the left atrial appendage: is it time to be more aggressive? *J Thorac Cardiovasc Surg.* 2013; 146(5): 1018–1027.e2, doi: [10.1016/j.jtcvs.2013.07.011](#), indexed in Pubmed: [23993272](#).
33. Madden JL. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. *J Am Med Assoc.* 1949; 140(9): 769–772, doi: [10.1001/jama.1949.02900440011003](#), indexed in Pubmed: [18152330](#).
34. Johnson WD, Ganjoo AK, Stone CD, et al. The left atrial appendage: our most lethal human attachment! Surgical implications. *Eur J Cardiothorac Surg.* 2000; 17(6): 718–722, doi: [10.1016/s1010-7940\(00\)00419-x](#), indexed in Pubmed: [10856866](#).
35. Schneider B, Stollberger C, Sievers HH. Surgical closure of the left atrial appendage - a beneficial procedure? *Cardiology.* 2005; 104(3): 127–132, doi: [10.1159/000087632](#), indexed in Pubmed: [16118490](#).
36. Almahameed ST, Khan M, Zuzek RW, et al. Left atrial appendage exclusion and the risk of thromboembolic events following mitral valve surgery. *J Cardiovasc Electrophysiol.* 2007; 18(4): 364–366, doi: [10.1111/j.1540-8167.2006.00755.x](#), indexed in Pubmed: [17286567](#).
37. Gillinov AM, Gelijns AC, Parides MK, et al. CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. *N Engl J Med.* 2015; 372(15): 1399–1409, doi: [10.1056/NEJMoa1500528](#), indexed in Pubmed: [25853744](#).
38. Melduni RM, Schaff HV, Lee HC, et al. Impact of Left Atrial Appendage Closure During Cardiac Surgery on the Occurrence of Early Postoperative Atrial Fibrillation, Stroke, and Mortality: A Propensity Score-Matched Analysis of 10633 Patients. *Circulation.* 2017; 135(4): 366–378, doi: [10.1161/CIRCULATIONAHA.116.021952](#), indexed in Pubmed: [27903589](#).
39. Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? *Interact Cardiovasc Thorac Surg.* 2010; 10(2): 306–311, doi: [10.1510/icvts.2009.227991](#), indexed in Pubmed: [19942634](#).
40. Katz ES, Tsiamsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. *J Am Coll Cardiol.* 2000; 36(2): 468–471, doi: [10.1016/s0735-1097\(00\)00765-8](#), indexed in Pubmed: [10933359](#).
41. García-Fernández MA, Pérez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. *J Am Coll Cardiol.* 2003; 42(7): 1253–1258, doi: [10.1016/s0735-1097\(03\)00954-9](#), indexed in Pubmed: [14522491](#).
42. Koz C, Baysan O, Yokusoglu M, et al. Left atrial appendage can still cause clinical events after ligation. *Eur J Echocardiogr.* 2008; 9(1): 194–195, doi: [10.1093/ejehocardi/jem069](#), indexed in Pubmed: [18267922](#).
43. Aryana A, Singh SK, Singh SM, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. *Heart Rhythm.* 2015; 12(7): 1431–1437, doi: [10.1016/j.hrthm.2015.03.028](#), indexed in Pubmed: [25998141](#).
44. Tsai YC, Phan K, Munkholm-Larsen S, et al. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. *Eur J Cardiothorac Surg.* 2015; 47(5): 847–854, doi: [10.1093/ejcts/ezu291](#), indexed in Pubmed: [25064051](#).
45. Kanderian AS, Gillinov AM, Pettersson GB, et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. *J Am Coll Cardiol.* 2008; 52(11): 924–929, doi: [10.1016/j.jacc.2008.03.067](#), indexed in Pubmed: [18772063](#).
46. Ohtsuka T, Ninomiya M, Nonaka T, et al. Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. *J Am Coll Cardiol.* 2013; 62(2): 103–107, doi: [10.1016/j.jacc.2013.01.017](#), indexed in Pubmed: [23433566](#).
47. Whitlock R, Healey J, Vincent J, et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. *Ann Cardiothorac Surg.* 2014; 3(1): 45–54, doi: [10.3978/j.issn.2225-319X.2013.12.06](#), indexed in Pubmed: [24516797](#).
48. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J.* 2012; 33(19): 2451–2496, doi: [10.1093/eurheartj/ehs109](#), indexed in Pubmed: [22922415](#).
49. Dunning J, Nagendran M, Alfieri OR, et al. EACTS Clinical Guidelines Committee. Guideline for the surgical treatment of atrial fibrillation. *Eur J Cardiothorac Surg.* 2013; 44(5): 777–791, doi: [10.1093/ejcts/ezt413](#), indexed in Pubmed: [23956274](#).
50. Ventosa-Fernandez G, Quintana E, Castellá M, et al. Exclusion of the left atrial appendage with the TigerPaw II system: a word of caution. *Interact Cardiovasc Thorac Surg.* 2015; 21(6): 803–804, doi: [10.1093/icvts/ivv256](#), indexed in Pubmed: [26395944](#).
51. Salzberg SP, Plass A, Emmert MY, et al. Left atrial appendage clip occlusion: early clinical results. *J Thorac Cardiovasc Surg.* 2010; 139(5): 1269–1274, doi: [10.1016/j.jtcvs.2009.06.033](#), indexed in Pubmed: [19880144](#).
52. Ailawadi G, Gerdisch MW, Harvey RL, et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. *J Thorac Cardiovasc Surg.* 2011; 142(5): 1002–9, 1009.e1, doi: [10.1016/j.jtcvs.2011.07.052](#), indexed in Pubmed: [21906756](#).
53. Emmert MY, Puippe G, Baumüller S, et al. Safe, effective and durable epicardial left atrial appendage clip occlusion in patients with atrial fibrillation undergoing cardiac surgery: first long-term results from a prospective device trial. *Eur J Cardiothorac Surg.* 2014; 45(1): 126–131, doi: [10.1093/ejcts/ezt204](#), indexed in Pubmed: [23657550](#).
54. Pracon R, Bangalore S, Henzel J, et al. A randomized comparison of modified subcutaneous. *Catheter Cardiovasc Interv.* 2018; 91(1): 105–112, doi: [10.1002/ccd.27003](#), indexed in Pubmed: [28303670](#).
55. Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. *Catheter Cardiovasc*

- Interv. 2003; 60(3): 417–422, doi: [10.1002/ccd.10660](#), indexed in Pubmed: [14571497](#).
56. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. *Catheter Cardiovasc Interv.* 2011; 77(5): 700–706, doi: [10.1002/ccd.22764](#), indexed in Pubmed: [20824765](#).
 57. Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet.* 2009; 374(9689): 534–542, doi: [10.1016/S0140-6736\(09\)61343-X](#), indexed in Pubmed: [19683639](#).
 58. Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. *JAMA.* 2014; 312(19): 1988–1998, doi: [10.1001/jama.2014.15192](#), indexed in Pubmed: [25399274](#).
 59. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation.* 2011; 123(4): 417–424, doi: [10.1161/CIRCULATIONAHA.110.976449](#), indexed in Pubmed: [21242484](#).
 60. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. *J Am Coll Cardiol.* 2014; 64(1): 1–12, doi: [10.1016/j.jacc.2014.04.029](#), indexed in Pubmed: [24998121](#).
 61. Reddy VY, Gibson DN, Kar S, et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. *J Am Coll Cardiol.* 2017; 69(3): 253–261, doi: [10.1016/j.jacc.2016.10.010](#), indexed in Pubmed: [27816552](#).
 62. Grygier M, Ołasińska-Wiśniewska A, Araszkiewicz A, et al. The Watchman FLX - a new device for left atrial appendage occlusion - design, potential benefits and first clinical experience. *Postępy Kardiologii Interwencyjnej.* 2017; 13(1): 62–66, doi: [10.5114/aic.2017.66188](#), indexed in Pubmed: [28344619](#).
 63. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. *EuroIntervention.* 2016; 11(10): 1170–1179, doi: [10.4244/EIJY15M01_06](#), indexed in Pubmed: [25604089](#).
 64. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. *Catheter Cardiovasc Interv.* 2013; 82(2): 283–289, doi: [10.1002/ccd.24872](#), indexed in Pubmed: [23412815](#).
 65. Meerkink D, Butnaru A, Dratva D, et al. Early safety of the Amplatzer Cardiac Plug™ for left atrial appendage occlusion. *Int J Cardiol.* 2013; 168(4): 3920–3925, doi: [10.1016/j.ijcard.2013.06.062](#), indexed in Pubmed: [23890886](#).
 66. Lam YY, Yip GWK, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. *Catheter Cardiovasc Interv.* 2012; 79(5): 794–800, doi: [10.1002/ccd.23136](#), indexed in Pubmed: [21542102](#).
 67. Demkow M, Witkowski A, Cedzyński Ł, et al. [Transcatheter closure of left atrial appendage with the Amplatzer Cardiac Plug in patients with atrial fibrillation and high risk of thromboembolic events—early experience]. *Kardiologia Pol.* 2010; 68(2): 250–254, indexed in Pubmed: [20301041](#).
 68. Urena M, Rodés-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. *J Am Coll Cardiol.* 2013; 62(2): 96–102, doi: [10.1016/j.jacc.2013.02.089](#), indexed in Pubmed: [23665098](#).
 69. Streb W, Szymała M, Kukulski T, et al. Percutaneous closure of the left atrial appendage using the Amplatzer Cardiac Plug in patients with atrial fibrillation: evaluation of safety and feasibility. *Kardiologia Pol.* 2013; 71(1): 8–16, indexed in Pubmed: [23348528](#).
 70. Freixa X, Chan JLK, Tzikas A, et al. The Amplatzer™ Cardiac Plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. *EuroIntervention.* 2013; 8(9): 1094–1098, doi: [10.4244/EIJV8I9A167](#), indexed in Pubmed: [23339815](#).
 71. Lam SC, Bertog S, Gafoor S, et al. Left atrial appendage closure using the Amulet device: an initial experience with the second generation amplatzer cardiac plug. *Catheter Cardiovasc Interv.* 2015; 85(2): 297–303, doi: [10.1002/ccd.25644](#), indexed in Pubmed: [25158644](#).
 72. Tzikas A, Karagounis L, Bouktsi M, et al. Left atrial appendage occlusion with the Amplatzer Amulet for stroke prevention in atrial fibrillation: the first case in Greece. *Hellenic J Cardiol.* 2013; 54(5): 408–412, indexed in Pubmed: [24100187](#).
 73. Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™. *Int J Cardiol.* 2014; 174(3): 492–496, doi: [10.1016/j.ijcard.2014.03.154](#), indexed in Pubmed: [24820753](#).
 74. Abualsaud A, Freixa X, Tzikas A, et al. Side-by-Side Comparison of LAA Occlusion Performance With the Amplatzer Cardiac Plug and Amplatzer Amulet. *J Invasive Cardiol.* 2016; 28(1): 34–38, indexed in Pubmed: [26716593](#).
 75. Freixa X, Kwai Chan JL, Tzikas A, et al. Percutaneous closure of a very large left atrial appendage using the Amplatzer amulet. *Can J Cardiol.* 2013; 29(10): 1329.e9–1329.e11, doi: [10.1016/j.cjca.2012.12.022](#), indexed in Pubmed: [23541662](#).
 76. Freixa X, Tzikas A, Basmaadjian A, et al. The chicken-wing morphology: an anatomical challenge for left atrial appendage occlusion. *J Interv Cardiol.* 2013; 26(5): 509–514, doi: [10.1111/joic.12055](#), indexed in Pubmed: [24033805](#).
 77. Pracon R, Grygoruk R, Dzielińska Z, et al. Percutaneous occlusion of the left atrial appendage with complex anatomy facilitated with 3D-printed model of the heart. *EuroIntervention.* 2016; 12(7): 927, doi: [10.4244/EIJV12I7A152](#), indexed in Pubmed: [27639747](#).
 78. Gafoor S, Heuer L, Franke J. Novel Percutaneous LAA Closure Devices in Clinical or Preclinical Trials, in *Left Atrial Appendage Closure. Mechanical Approaches to Stroke Prevention in Atrial Fibrillation*, J. Saw, S. Kar, and M.J. Price, Editors. 2016, Springer International Publishing: Switzerland. Springer International Publishing, Switzerland 2016: 233–245.
 79. Syed FF, Noheria A, DeSimone CV, et al. Left Atrial Appendage Ligation And Exclusion Technology In The Incubator. *J Atr Fibrillation.* 2015; 8(2): 1160–70, doi: [10.4022/jafib.1160](#), indexed in Pubmed: [27957184](#).
 80. Sabiniewicz R, Hiczkiewicz J, Wańczura P, et al. First-in-human experience with the Cardia Ultraseal left atrial appendage closure device: The feasibility study. *Cardiol J.* 2016; 23(6): 652–654, doi: [10.5603/CJ.2016.0106](#), indexed in Pubmed: [27976795](#).
 81. Meier B, Blaauw Y, Khattab AA, et al. Document Reviewers. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. *EuroIntervention.* 2015; 10(9): 1109–1125, doi: [10.4244/EIJY14M08_18](#), indexed in Pubmed: [25169595](#).
 82. Bergmann MW, Landmesser U. Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. *EuroIntervention.* 2014; 10(4): 497–504, doi: [10.4244/EIJV10I4A86](#), indexed in Pubmed: [25138187](#).
 83. WaveCrest Coherex. <http://www.medgadget.com/2013/09/coherex-left-atrial-appendage-occluder-gets-ce-mark.html>.
 84. Reddy V, Franzen O. Clinical experience with the Wavecrest LA appendage occlusion device for stroke prevention in AF: acute results of the WAVECREST I trial, in *Heart Rhythm Society 35th Annual Scientific Sessions.*, San Francisco 2014: PO01–112.

85. Notatka bezpieczeństwa. Document ID: FSN-20160928_DE. <http://www.urpl.gov.pl/pl>.
86. LAMBRE Lifetech. <http://www.lifetechmed.com>.
87. Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model. *Circ Cardiovasc Interv*. 2010; 3(3): 224–229, doi: [10.1161/CIRCINTERVENTIONS.109.914978](#), indexed in Pubmed: [20484100](#).
88. Lee R, Yakubov S, Bartus K, et al. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA. *J Am Coll Cardiol*. 2010; 55(10): A1.E5, doi: [10.1016/s0735-1097\(10\)60006-x](#).
89. Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. *Heart Rhythm*. 2011; 8(2): 188–193, doi: [10.1016/j.hrthm.2010.10.040](#), indexed in Pubmed: [21050893](#).
90. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. *J Am Coll Cardiol*. 2013; 62(2): 108–118, doi: [10.1016/j.jacc.2012.06.046](#), indexed in Pubmed: [23062528](#).
91. Bartus K, Sadowski J, Kapelak B. Nowe techniki zamykania uszka lewego przedsionka. Od eksperymentu do kliniki. In: Dłużniewski M, Syska-Sumińska J, Kalarus Z. ed. *Migotanie przedsionków: codzienność lekarza praktyka*. CZELEJ, Lublin 2013: 153–157.
92. Bartus K, Sadowski J, Kapelak B. Kardiochirurgia dla chorych z migotaniem przedsionków - czy tylko przy operacji wady? In: Dłużniewski M, Syska-Sumińska J, Kalarus Z. ed. *Migotanie przedsionków: codzienność lekarza praktyka*. CZELEJ, Lublin 2013: 269–273.
93. Han FT, Bartus K, Lakkireddy D, et al. The effects of LAA ligation on LAA electrical activity. *Heart Rhythm*. 2014; 11(5): 864–870, doi: [10.1016/j.hrthm.2014.01.019](#), indexed in Pubmed: [24444443](#).
94. Bartus K, Morelli RL, Szczepanski W, et al. Anatomic analysis of the left atrial appendage after closure with the LARIAT device. *Circ Arrhythm Electrophysiol*. 2014; 7(4): 764–767, doi: [10.1161/CIRCEP.113.001084](#), indexed in Pubmed: [25140024](#).
95. Gunda S, Reddy M, Pillarisetti J, et al. Differences in complication rates between large bore needle and a long micropuncture needle during epicardial access: time to change clinical practice? *Circ Arrhythm Electrophysiol*. 2015; 8(4): 890–895, doi: [10.1161/CIRCEP.115.002921](#), indexed in Pubmed: [26078278](#).
96. Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. *Heart Rhythm*. 2015; 12(7): 1501–1507, doi: [10.1016/j.hrthm.2015.03.020](#), indexed in Pubmed: [25778430](#).
97. Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices. *Heart Rhythm*. 2015; 12(1): 52–59, doi: [10.1016/j.hrthm.2014.09.053](#), indexed in Pubmed: [25281005](#).
98. Sievert H, Rasekh A, Bartus K, et al. Left Atrial Appendage Ligation in Nonvalvular Atrial Fibrillation Patients at High Risk for Embolic Events With Ineligibility for Oral Anticoagulation. *JACC: Clinical Electrophysiology*. 2015; 1(6): 465–474, doi: [10.1016/j.jacep.2015.08.005](#).
99. Lakkireddy D, Mahankali AS, Kanmanthareddy A, et al. Left Atrial Appendage Ligation and Ablation for Persistent Atrial Fibrillation. *JACC: Clinical Electrophysiology*. 2015; 1(3): 153–160, doi: [10.1016/j.jacep.2015.04.006](#).
100. Lee RJ, Bartus K, Badhwar N. Transpericardial access. In: Sievert H, Quresh SA, Wilson N, Hijazi ZM. ed. *Interventions in structural, valvular, and congenital heart disease*. Taylor & Francis 2015: 173–179.
101. Bartus K, Lee RJ. Sentre heart. In: Sievert H, Quresh SAJ, Wilson N, Hijazi ZM. ed. *Interventions in structural, valvular, and congenital heart disease*. Taylor & Francis 2015: 819–827.
102. Bartus K, Sadowski J, Litwinowicz R. Zamykanie uszka lewego przedsionka u chorych z migotaniem przedsionków. In: Kapłon-Wozakowska B. ed. *Migotanie przedsionków*. VM Media VM Group Grupa Via Medica, Gdańsk 2016: 130–141.
103. Bartus K, Gafoor S, Tschopp D, et al. Left atrial appendage ligation with the next generation LARIAT(+) suture delivery device: Early clinical experience. *Int J Cardiol*. 2016; 215: 244–247, doi: [10.1016/j.ijcard.2016.04.005](#), indexed in Pubmed: [27128539](#).
104. Bartuś K. Left atrial appendage occlusion procedures. *Kardiochir Torakochirurgia Pol*. 2017; 14(1): 1–4, doi: [10.5114/kitp.2017.66921](#), indexed in Pubmed: [28515740](#).
105. Beutler D, Gerkin R, Loli A. The Morphology of Left Atrial Appendage Lobes: A Novel Characteristic Naming Scheme Derived through Three-Dimensional Cardiac Computed Tomography. *World J Cardiovasc Surg*. 2014; 04(03): 17–24, doi: [10.4236/wjcs.2014.43004](#).
106. Wunderlich NC, Beigel R, Swaans MJ, et al. Percutaneous interventions for left atrial appendage exclusion: options, assessment, and imaging using 2D and 3D echocardiography. *JACC Cardiovasc Imaging*. 2015; 8(4): 472–488, doi: [10.1016/j.jcmg.2015.02.002](#), indexed in Pubmed: [25882576](#).
107. Beigel R, Wunderlich NC, Ho SY, et al. The left atrial appendage: anatomy, function, and noninvasive evaluation. *JACC Cardiovasc Imaging*. 2014; 7(12): 1251–1265, doi: [10.1016/j.jcmg.2014.08.009](#), indexed in Pubmed: [25496544](#).
108. Spencer RJ, DeJong P, Fahmy P, et al. Changes in Left Atrial Appendage Dimensions Following Volume Loading During Percutaneous Left Atrial Appendage Closure. *JACC Cardiovasc Interv*. 2015; 8(15): 1935–1941, doi: [10.1016/j.jcin.2015.07.035](#), indexed in Pubmed: [26738661](#).
109. Chue CD, de Giovanni J, Steeds RP. The role of echocardiography in percutaneous left atrial appendage occlusion. *Eur J Echocardiogr*. 2011; 12(10): i3–10, doi: [10.1093/ejecho-card/yer090](#), indexed in Pubmed: [21998466](#).
110. Nucifora G, Faletra FF, Regoli F, et al. Evaluation of the left atrial appendage with real-time 3-dimensional transesophageal echocardiography: implications for catheter-based left atrial appendage closure. *Circ Cardiovasc Imaging*. 2011; 4(5): 514–523, doi: [10.1161/CIRCIMAGING.111.963892](#), indexed in Pubmed: [21737601](#).
111. van Rosendael PJ, Katsanos S, van den Brink OWV, et al. Geometry of left atrial appendage assessed with multidetector-row computed tomography: implications for transcatheter closure devices. *EuroIntervention*. 2014; 10(3): 364–371, doi: [10.4244/EIJV10I3A62](#), indexed in Pubmed: [24273250](#).
112. Ho ICK, Neuzil P, Mraz T, et al. Use of intracardiac echocardiography to guide implantation of a left atrial appendage occlusion device (PLAATO). *Heart Rhythm*. 2007; 4(5): 567–571, doi: [10.1016/j.hrthm.2007.01.014](#), indexed in Pubmed: [17467621](#).
113. Blendea D, Heist EK, Danik SB, et al. Analysis of the left atrial appendage morphology by intracardiac echocardiography in patients with atrial fibrillation. *J Interv Card Electrophysiol*. 2011; 31(3): 191–196, doi: [10.1007/s10840-011-9559-z](#), indexed in Pubmed: [21455699](#).
114. Perk G, Biner S, Kronzon I, et al. Catheter-based left atrial appendage occlusion procedure: role of echocardiography. *Eur Heart J Cardiovasc Imaging*. 2012; 13(2): 132–138, doi: [10.1093/ejecho-card/yer158](#), indexed in Pubmed: [21903725](#).
115. Perk G, Lang RM, Garcia-Fernandez MA, et al. Use of real time three-dimensional transesophageal echocardiography in intracardiac catheter based interventions. *J Am Soc Echocardiogr*. 2009; 22(8): 865–882, doi: [10.1016/j.echo.2009.04.031](#), indexed in Pubmed: [19647156](#).

116. Nucifora G, Faletra FF, Regoli F, et al. Evaluation of the left atrial appendage with real-time 3-dimensional transesophageal echocardiography: implications for catheter-based left atrial appendage closure. *Circ Cardiovasc Imaging*. 2011; 4(5): 514–523, doi: [10.1161/CIRCIMAGING.111.963892](#), indexed in Pubmed: [21737601](#).
117. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. *JACC Cardiovasc Interv*. 2009; 2(7): 594–600, doi: [10.1016/j.jcin.2009.05.005](#), indexed in Pubmed: [19628179](#).
118. López-Mínguez JR, Eldoayen-Gragera J, González-Fernández R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer cardiac plug. *Rev Esp Cardiol (Engl Ed)*. 2013; 66(2): 90–97, doi: [10.1016/j.rec.2012.04.017](#), indexed in Pubmed: [24775381](#).
119. van Rosendael PJ, Katsanos S, van den Brink OWV, et al. Geometry of left atrial appendage assessed with multidetector-row computed tomography: implications for transcatheter closure devices. *EuroIntervention*. 2014; 10(3): 364–371, doi: [10.4244/EIJ-V10I3A62](#), indexed in Pubmed: [24273250](#).
120. Ismail TF, Panikker S, Markides V, et al. CT imaging for left atrial appendage closure: a review and pictorial essay. *J Cardiovasc Comput Tomogr*. 2015; 9(2): 89–102, doi: [10.1016/j.jcct.2015.01.011](#), indexed in Pubmed: [25819192](#).
121. Mohrs OK, Wunderlich N, Petersen SE, et al. Contrast-enhanced CMR in patients after percutaneous closure of the left atrial appendage: a pilot study. *J Cardiovasc Magn Reson*. 2011; 13: 33, doi: [10.1186/1532-429X-13-33](#), indexed in Pubmed: [21726450](#).
122. Rath VK, Reddy ST, Anreddy S, et al. Contrast-enhanced CMR is equally effective as TEE in the evaluation of left atrial appendage thrombus in patients with atrial fibrillation undergoing pulmonary vein isolation procedure. *Heart Rhythm*. 2013; 10(7): 1021–1027, doi: [10.1016/j.hrthm.2013.02.029](#), indexed in Pubmed: [23454807](#).
123. Lange M, Büttel H, Weglage H, et al. Closure of Left Atrial Appendage With Persistent Distal Thrombus Using an Amplatzer Amulet Occluder. *J Invasive Cardiol*. 2016; 28(9): E75–E76, indexed in Pubmed: [27591691](#).
124. Jalal Z, Iriat X, Dinat ML, et al. Extending percutaneous left atrial appendage closure indications using the AMPLATZER™ Cardiac Plug device in patients with persistent left atrial appendage thrombus: The thrombus trapping technique. *Arch Cardiovasc Dis*. 2016; 109(12): 659–666, doi: [10.1016/j.acvd.2016.02.012](#), indexed in Pubmed: [27402154](#).
125. Krothapalli S, Bhav PD. A Comparison Between NOACs and Warfarin on Time to Elective Cardioversion. *J Atr Fibrillation*. 2016; 9(2): 1451, doi: [10.4022/jafib.1451](#), indexed in Pubmed: [27909537](#).
126. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet*. 2009; 373(9658): 155–166, doi: [10.1016/S0140-6736\(09\)60040-4](#), indexed in Pubmed: [19135613](#).
127. Ren JF, Marchlinski FE, Callans DJ, et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. *J Cardiovasc Electrophysiol*. 2005; 16(5): 474–477, doi: [10.1046/j.1540-8167.2005.40465.x](#), indexed in Pubmed: [15877616](#).
128. Ichiki H, Oketani N, Ishida S, et al. Incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation guided by complex fractionated atrial electrogram. *J Cardiovasc Electrophysiol*. 2012; 23(6): 567–573, doi: [10.1111/j.1540-8167.2011.02259.x](#), indexed in Pubmed: [22313240](#).
129. Meincke F, Spangenberg T, Kreidel F, et al. Rationale of cerebral protection devices in left atrial appendage occlusion. *Catheter Cardiovasc Interv*. 2017; 89(1): 154–158, doi: [10.1002/ccd.26677](#), indexed in Pubmed: [27762092](#).
130. Kar S, Hou D, Jones R, et al. Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. *JACC Cardiovasc Interv*. 2014; 7(7): 801–809, doi: [10.1016/j.jcin.2014.03.003](#), indexed in Pubmed: [25060026](#).
131. Massarenti L, Yilmaz A. Incomplete endothelialization of left atrial appendage occlusion device 10 months after implantation. *J Cardiovasc Electrophysiol*. 2012; 23(12): 1384–1385, doi: [10.1111/j.1540-8167.2012.02360.x](#), indexed in Pubmed: [22612654](#).
132. Lammers J, Elenbaas T, Meijer A. Thrombus formation on an Amplatzer closure device after left atrial appendage closure. *Eur Heart J*. 2013; 34(10): 741, doi: [10.1093/eurheartj/ehs437](#), indexed in Pubmed: [23242193](#).
133. Plicht B, Konorza TFM, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion. *JACC Cardiovasc Interv*. 2013; 6(6): 606–613, doi: [10.1016/j.jcin.2013.02.014](#), indexed in Pubmed: [23787233](#).
134. Main ML, Fan D, Reddy VY, et al. Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial). *Am J Cardiol*. 2016; 117(7): 1127–1134, doi: [10.1016/j.amjcard.2016.01.039](#), indexed in Pubmed: [26993976](#).
135. Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation. *Heart Rhythm*. 2016; 13(5): 1030–1036, doi: [10.1016/j.hrthm.2016.01.022](#), indexed in Pubmed: [26872554](#).
136. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. *J Am Coll Cardiol*. 2012; 59(10): 923–929, doi: [10.1016/j.jacc.2011.11.028](#), indexed in Pubmed: [22381428](#).
137. Bösch LI, Afshari F, Schöne D, et al. Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device. *Clin Cardiol*. 2015; 38(12): 720–724, doi: [10.1002/clc.22478](#), indexed in Pubmed: [26467851](#).
138. Enomoto Y, Gadiyaram VK, Gianni C, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. *Heart Rhythm*. 2017; 14(1): 19–24, doi: [10.1016/j.hrthm.2016.10.020](#), indexed in Pubmed: [27771552](#).
139. Wiebe J, Bertog S, Franke J, et al. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. *Catheter Cardiovasc Interv*. 2014; 83(5): 796–802, doi: [10.1002/ccd.25329](#), indexed in Pubmed: [24327462](#).
140. Osmancik P, Tousek P, Herman D, et al. PRAGUE-17 Investigators. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). *Am Heart J*. 2017; 183: 108–114, doi: [10.1016/j.ahj.2016.10.003](#), indexed in Pubmed: [27979034](#).
141. Pison L, Potpara TS, Chen J, et al. Scientific Initiative Committee, European Heart Rhythm Association. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. *Europace*. 2015; 17(4): 642–646, doi: [10.1093/europace/euv069](#), indexed in Pubmed: [25833883](#).
142. Connolly SJ, Pogue J, Hart RG, et al. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

- N Engl J Med. 2009; 360(20): 2066–2078, doi: [10.1056/NEJMoa0901301](https://doi.org/10.1056/NEJMoa0901301), indexed in Pubmed: [19336502](https://pubmed.ncbi.nlm.nih.gov/19336502/).
143. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012; 172(3): 209–216, doi: [10.1001/archinternmed.2011.628](https://doi.org/10.1001/archinternmed.2011.628), indexed in Pubmed: [22231610](https://pubmed.ncbi.nlm.nih.gov/22231610/).
 144. Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. *Heart Rhythm*. 2013; 10(12): 1792–1799, doi: [10.1016/j.hrthm.2013.08.025](https://doi.org/10.1016/j.hrthm.2013.08.025), indexed in Pubmed: [23973952](https://pubmed.ncbi.nlm.nih.gov/23973952/).
 145. Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. *EuroIntervention*. 2017; 12(17): 2075–2082, doi: [10.4244/EIJ-D-16-00726](https://doi.org/10.4244/EIJ-D-16-00726), indexed in Pubmed: [27973336](https://pubmed.ncbi.nlm.nih.gov/27973336/).
 146. Qazi AH, Wimmer AP, Huber KC, et al. Resolution (and Late Recurrence) of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran. *Echocardiography*. 2016; 33(5): 792–795, doi: [10.1111/echo.13174](https://doi.org/10.1111/echo.13174), indexed in Pubmed: [26775639](https://pubmed.ncbi.nlm.nih.gov/26775639/).
 147. Vaquerizo B, Sami M. Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban. *J Atr Fibrillation*. 2015; 8(1): 1182, doi: [10.4022/jafib.1182](https://doi.org/10.4022/jafib.1182), indexed in Pubmed: [27957170](https://pubmed.ncbi.nlm.nih.gov/27957170/).
 148. Wunderlich N, Wilson N, Sievert H. A novel approach to treat residual peridevice leakage after left-atrial appendage closure. *Catheter Cardiovasc Interv*. 2013; 82(2): 313–319, doi: [10.1002/ccd.23014](https://doi.org/10.1002/ccd.23014), indexed in Pubmed: [23629764](https://pubmed.ncbi.nlm.nih.gov/23629764/).
 149. Waksman R, Pendyala LK. Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy. *Am J Cardiol*. 2015; 115(3): 378–384, doi: [10.1016/j.amjcard.2014.11.011](https://doi.org/10.1016/j.amjcard.2014.11.011), indexed in Pubmed: [25579887](https://pubmed.ncbi.nlm.nih.gov/25579887/).
 150. Daoud EG, Glotzer TV, Wyse DG, et al. TRENDS Investigators. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. *Heart Rhythm*. 2011; 8(9): 1416–1423, doi: [10.1016/j.hrthm.2011.04.022](https://doi.org/10.1016/j.hrthm.2011.04.022), indexed in Pubmed: [21699833](https://pubmed.ncbi.nlm.nih.gov/21699833/).
 151. Brambatti M, Connolly SJ, Gold MR, et al. ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. *Circulation*. 2014; 129(21): 2094–2099, doi: [10.1161/CIRCULATIONAHA.113.007825](https://doi.org/10.1161/CIRCULATIONAHA.113.007825), indexed in Pubmed: [24633881](https://pubmed.ncbi.nlm.nih.gov/24633881/).
 152. Holmes DR, Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. *J Am Coll Cardiol*. 2015; 65(24): 2614–2623, doi: [10.1016/j.jacc.2015.04.025](https://doi.org/10.1016/j.jacc.2015.04.025), indexed in Pubmed: [26088300](https://pubmed.ncbi.nlm.nih.gov/26088300/).
 153. Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet*. 2007; 370(9586): 493–503, doi: [10.1016/S0140-6736\(07\)61233-1](https://doi.org/10.1016/S0140-6736(07)61233-1), indexed in Pubmed: [17693178](https://pubmed.ncbi.nlm.nih.gov/17693178/).